Memo Therapeutics raises CHF 20 million in Series C extension financing
Amount Raised
CHF20 Million
Round Type
Series C
SchlierenBiotechnologyHealth CareScience And EngineeringInvestors
Description
Memo Therapeutics AG has successfully raised CHF 20 million as part of an extension of its Series C financing, bringing the total amount raised in the funding round to CHF 45 million. The new funding will support the clinical advancement of MTx’s lead asset, AntiBKV, and the development of MTx’s pipeline by leveraging its B-cell screening platform to select best-in-class humanized antibodies in other viral infections and oncology.
Quick answer
Memo Therapeutics AG raised CHF20 Million in a Series C round, dated May 7, 2024. Investors: Red Alpine, Fresenius Medical Care Ventures, Gf Group, Schroders Capital, Verve Ventures, Adjuvant Capital, Vesalius Biocapital and Swisscanto. Memo Therapeutics AG is based in Schlieren, Zurich, Switzerland.
- How much did Memo Therapeutics AG raise?
- Memo Therapeutics AG raised CHF20 Million in a Series C round on May 7, 2024.
- Who invested in Memo Therapeutics AG?
- Red Alpine, Fresenius Medical Care Ventures, Gf Group, Schroders Capital, Verve Ventures, Adjuvant Capital, Vesalius Biocapital and Swisscanto are named as investors in this round.
- What does Memo Therapeutics AG do?
- Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis.
- Where is Memo Therapeutics AG based and how big is it?
- Memo Therapeutics AG is based in Schlieren, Zurich, Switzerland.
- Who are the decision-makers at Memo Therapeutics AG?
- Fundz holds 1 contact at Memo Therapeutics AG. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Science And Engineering and Biotechnology around the same time
Companies in the same sectors as Memo Therapeutics AG that raised within 45 days of this round, from Fundz verified event records.
- Alzamend Neuro raised $25M (Series A) on May 9, 2024.
- Variantyx raised $36M (Funding Round) on April 26, 2024.
- Sydnexis raised $1000K (Series B) on April 24, 2024.
- DeepCure raised $25M (Series A) on April 11, 2024.
- 22nd Century raised $4.2M (Seed) on April 8, 2024.
- Nucleai raised $14M (Funding Round) on April 3, 2024.
Who to call at Memo Therapeutics AG, and when
A new round usually means Memo Therapeutics AG is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Memo Therapeutics AG raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Memo Therapeutics AG, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Memo Therapeutics AG. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Memo Therapeutics AG raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Memo Therapeutics AG raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.